MET and non-small cell lung carcinoma: Other emerging targeted therapies for NSCLC target gene aberrations associated with ERBB2 (HER2), mesenchymal–epithelial transition (MET), rearranged during transfection (RET), KRASG12C, NeuReGulin 1(NRG1), and the fibroblast growth factor receptor (FGFR) [8].